BaseCare Medical (2170.HK) Unveils First Smart Home Sperm Analyzer, Pioneering "B+C" Full-Scenario Intelligent Expansion

SUZHOU, China, April 9, 2025 /PRNewswire/ -- BaseCare Medical, a trailblazer in reproductive health and China's first publicly traded company in the assisted reproductive IVD sector, has secured regulatory approval for its portable home sperm quality analyzer (model: BKP200). As the nation's first consumer-facing device for at-home viable sperm testing, this milestone not only underscores the company's technical prowess in male reproductive health but also carves out a new frontier for the home medical equipment market.

Data from Guangdong Reproductive Hospital reveals a stark reality: nearly half of couples attempting a second child have failed in the past three years, while one-third of men preparing for their first pregnancy exhibit subpar sperm quality. Yet due to embarrassment, many choose to overlook these issues rather than seek help.

Gone are the days of awkward hospital visits and tedious waits for sperm tests. BaseCare's innovative home analyzer shrinks lab-grade technology into a compact device, bringing professional sperm assessment directly to living rooms.

Cutting-Edge Tech: Lab Precision, Home Convenience

Designed to meet the WHO Laboratory Manual for Human Semen Examination (6th Edition) standards, the BKP200 excels in portability, privacy, speed, accuracy, versatility, and clarity. Using a built-in HD camera and advanced algorithms, it delivers lab-level precision in just 15 seconds, generating visual reports on sperm concentration and motility. Unlike smartphone-based tests prone to inconsistent results, this device eliminates hardware-related errors, enabling hassle-free "15-second home self-tests" that respect privacy and offer actionable insights for long-term fertility management.

Policy Tailwinds & Market Demand: Dual "B+C" Growth Engines

With global male infertility rates climbing (7%-12% per WHO) and traditional testing hindered by limited access and privacy concerns, China—where infertility rates surpass the global average—has seen policy support surge. Since 2024, the National Health Commission has prioritized "comprehensive male health services across the lifespan" and included assisted reproductive technologies in medical insurance, creating ideal conditions for BaseCare's dual-market strategy.

The BKP200 bridges professional and personal use with its "medical-grade device for home use" model, available online (via Douyin, e-commerce platforms) and offline (in pharmacies). Here's how it works:

1.Hospital Support: In hospitals—especially in rural areas lacking specialized equipment—the analyzer streamlines pre-screening, freeing doctors to focus on treatment. It effectively extends reproductive healthcare to county and village levels, building a nationwide "fertility health monitoring network."

2.Consumer Access: Couples can discreetly assess fertility factors at home, while young men gain instant insights into their reproductive health. The accompanying app provides tailored advice like "reduce late nights, increase exercise," offering a seamless journey from testing to improvement.

Targeting China's 50 million fertility-challenged families, the device launches in about a month with a pragmatic approach: online, educational content and health influencers normalize conversations about male health; offline, it's stocked beside blood pressure monitors in pharmacies, making it as accessible as everyday health gadgets..

In essence, this innovation transforms reproductive health management from a "specialized medical process" into a "routine practice," turning "taboos" into "simple solutions."

BaseCare's vision goes beyond technology: it aims to make fertility health accessible to all—whether urban couples, concerned in-laws, or families in remote areas—with minimal cost and maximum scientific assurance, contributing to both individual family dreams and national population quality.

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

BaseCare Medical (2170.HK) Unveils First Smart Home Sperm Analyzer, Pioneering "B+C" Full-Scenario Intelligent Expansion

BaseCare Medical (2170.HK) Unveils First Smart Home Sperm Analyzer, Pioneering "B+C" Full-Scenario Intelligent Expansion

T. Rowe Price Investment Management, Inc. and Braidwell LP participate as new investors

Stephen Williams, MD, Ph.D. joins as Chief Scientific Officer

Rebecca Chambers and Frank Witney, Ph.D. appointed to Board of Directors

FREMONT, Calif., Jan. 12, 2026 /PRNewswire/ -- Alamar Biosciences, Inc. ("Alamar"), a leader in precision proteomics dedicated to advancing the early detection of disease, announced the close of an oversubscribed convertible notes financing, bringing in more than $50 million of new capital. Accounts advised by T. Rowe Price Investment Management, Inc. and Braidwell LP joined the financing as new investors. Existing investors, including Illumina Ventures and Sands Capital, also participated. The financing will support the continued commercial advancement of Alamar's precision proteomics platform.

"We deeply appreciate the continued support from our existing investors and are excited to welcome our new partners," said Dr. Yuling Luo, founder, chairman, and chief executive officer of Alamar. "Their confidence in our vision and strategy underscores the transformative potential of our work. This investment will enable us to accelerate innovation and continue to expand the reach of our platform, unlocking the full value of precision medicine and early disease detection."

Leadership and Board Expansion
Alamar also announced key additions to its executive leadership team and board of directors to support the company's continued growth and commitment to operational excellence.

 

 

To further strengthen its scientific leadership, Alamar welcomes Dr. Stephen Williams as Chief Scientific Officer. Steve brings more than three decades of experience in precision medicine and biomarker innovation. He most recently served as Chief Medical Officer at Standard BioTools and SomaLogic, and previously spent 18 years at Pfizer in senior leadership roles. A recognized leader in the scientific community, he has served on the NIH National Advisory Council for Biomedical Imaging and Bioengineering, helped launch the Alzheimer's Disease Neuroimaging Initiative, and co-founded the FDA-FNIH-PhRMA Biomarker Consortium.

Alamar has also appointed Rebecca Chambers and Dr. Frank Witney as directors to its board. Rebecca, Chief Financial Officer at Veracyte, brings deep financial and healthcare leadership experience from her current role as well as previous positions at Outset Medical, Illumina, Myriad Genetics and Life Technologies. Frank, an operating partner at Ampersand Capital Partners, adds over three decades of life sciences leadership experience, including serving as President and CEO of Affymetrix and Dionex Corporation, and currently sits on the boards of Revvity, Cerus Corporation, Standard BioTools, and several private companies.

"I am thrilled to welcome Steve to our leadership team, and Rebecca and Frank to our board of directors," said Dr. Yuling Luo. "Their deep expertise and diverse perspectives will be invaluable as we accelerate our mission to unleash the power of our Precision Proteomics platform, to enable broad impacts across health and disease. This is an exciting moment for Alamar, and we look forward to the impact their leadership will have on driving innovation and growth."

About Alamar Biosciences, Inc. 
Alamar Biosciences is a privately held life sciences company dedicated to powering precision proteomics to enable the earliest detection of disease. Leveraging its proprietary NULISA™ technology and the ARGO™ HT System, Alamar's platform is designed to deliver ultra-high sensitivity and addresses key limitations of existing technologies to deliver precision proteomics. For more information, please visit alamarbio.com. 

 

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team

Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team

Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team

Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team